Fatigue after initiating rivaroxaban for venous thromboembolism

BACKGROUND: Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Res Pract Thromb Haemost
Main Authors: Karlsvik, Tina Margrethe, Borgenvik, Thore Langfeldt, Aadalen, Mirjam, Utne, Kristin, Førsund, Eli, Jørgensen, Camilla Tøvik, Holst, René, Jelsness‐Jørgensen, Lars‐Petter, Ghanima, Waleed
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Article: Thrombosis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292653/
https://ncbi.nlm.nih.gov/pubmed/32548556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12312
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados